Researchers at the University of Maryland School of Medicine and the Institute of Human Virology have established the first successful human challenge model for dengue virus serotype 4. The experimental clinical model is designed to facilitate and accelerate the evaluation of candidate vaccines and targeted antiviral therapeutics against a viral strain that has historically posed persistent barriers to scientific study. Findings detailing the phase 1 dose optimisation and homologous rechallenge trial were published in The Lancet Microbe.
Dengue is a mosquito-borne flavivirus comprising four antigenically distinct serotypes designated DENV-1 through DENV-4. Dengue serotype 4 represents a unique public health and research hurdle because it circulates slowly and unpredictably, frequently with decades elapsing between recognized community outbreaks. Consequently, conventional large-scale field efficacy trials have encountered difficulties assessing vaccine performance, leaving recent phase 3 clinical trials unable to generate reliable efficacy estimates for this specific strain.
Conducted in Baltimore between April 2022 and December 2023, the study evaluated healthy adult volunteers to establish viral dynamics and clinical safety parameters. Participants received a single subcutaneous injection containing 95 plaque-forming units of the live challenge virus.
Following inoculation, volunteers were closely monitored under strict biosafety and containment precautions to prevent secondary environmental transmission. Participants underwent daily clinical assessments for emergent symptoms and had regular blood collections to measure viral kinetics. To ensure local mosquito populations could not acquire the virus and transmit it within the community, all study participants were accommodated in a local hotel during the window in which active virus remained detectable in their peripheral blood.
All 14 enrolled participants subsequently developed detectable viremia alongside mild-to-moderate dengue symptoms. Clinical manifestations followed a consistent presentation across the cohort, with rash and fatigue developing in every participant, followed in frequency by headaches.
To map immune mechanisms comprehensively, investigators paired clinical tracking with longitudinal immunological and transcriptomic profiling. After the initial viral challenge, participants mounted robust primary immune defenses characterized by significant antibody responses, marked expansion of antibody-producing cells, and widespread upregulation of antiviral genes.
The newly validated platform builds upon previous clinical models previously developed for dengue serotypes 1 and 3, forming part of a broader consortium effort focused on establishing human challenge frameworks for all four circulating serotypes.
Although the trial was conducted in a relatively small cohort of healthy adult volunteers and requires further validation, the established model provides a critical clinical foundation for ongoing flavivirus countermeasure research.
According to study principal investigator Kirsten E. Lyke, MD, Professor of Medicine at the Center for Vaccine Development and Global Health, the dengue virus ranks among the World Health Organization’s top ten global health threats. Lyke cautioned that a recent outbreak in Florida represents only an initial harbinger of the geographic spread of dengue projected to occur across the United States by 2080. Because medical science currently has no approved antiviral therapy to treat dengue infection, developing preventative vaccines remains critically important for protecting human populations both immediately and over the coming decades.
Lyke highlighted that controlled infection models allow investigators to test therapeutics, biologic agents, and vaccines in people so that researchers can focus energy and resources on advancing products with confirmed efficacy.
The phase 1 dose optimisation and homologous rechallenge trial was funded by the Military Infectious Disease Research Program and the Medical Technology Enterprise Consortium.
Subject of Research: Development of a human challenge model for dengue virus serotype 4
Article Title: University of Maryland School of Medicine researchers develop new human challenge model to advance dengue vaccine and treatment research
Article References: University of Maryland School of Medicine researchers develop new human challenge model to advance dengue vaccine and treatment research. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: Dengue virus, DENV-4, Human challenge model, Flavivirus, Vaccine development, Antiviral therapeutics, The Lancet Microbe, University of Maryland School of Medicine, Institute of Human Virology, Infectious diseases, Mosquito-borne illness, Clinical trials, Dose optimisation, Homologous rechallenge, Viral kinetics, Antibody response, Transcriptomic analysis, Immune protection

